ANI Pharmaceuticals, Inc.

Jurisdiction

United States

LEI

5493000T6CXTND40YH31

ISIN

US00182C1036

(ANIP)

Sectors

Scores

InsiderPie Expert Score: 44 / 100
Worse than peer group:: 50 / 100
Fair value (Benjamin Graham formula): N/A
Financial strength (Piotroski F-Value): 5 / 9
Fundamental strength relative to industry (Mohanram G-Value): 3 / 7

Profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. Read full profile

Fundamentals

Net revenue: €637.49M
Gross margin: 57.9%
EBIT: €12.96M
EBIT margin: 2.0%
Net income: -€9.41M
Net margin: -1.5%

Statement period: July 1, 2024 - June 30, 2025 (published August 8, 2025)

Estimates

Fiscal Year	Net revenue	Net income
2026	€786.44M +23.4%	€142.09M -1,610.2%
2027	€861.64M +9.6%	€166.51M +17.2%
2028	€911.93M +5.8%	€178.44M +7.2%

Dividends

No dividend payouts

Analyst ratings

No analyst ratings available

Insider Transactions

Name	Title	Transaction Date	Shares	Price	Value
Pera Antonio R	N/A	September 3, 2025	-7.3K	$94.94	-$692.30K
Leonard Matthew J	N/A	August 25, 2025	-2.5K	$90.62	-$229.09K
Davis Krista	SVP, CHIEF HR OFFICER	August 22, 2025	-1.8K	$91.10	-$160.61K
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	August 21, 2025	-100K	$90.36	-$9.04M
Pera Antonio R	N/A	August 20, 2025	-5.4K	$89.73	-$486.43K